This study examined the effects of oral estradiol combined with either micronized progesterone or medroxyprogesterone acetate on breast cancer risk markers in postmenopausal monkeys. Results showed that estradiol with medroxyprogesterone acetate significantly increased breast epithelial proliferation and expression of proliferation markers (Ki67, cyclin B1) compared to placebo (P < 0.01),
